What is AllerQuest?
AllerQuest, LLC operates at the intersection of pharmaceutical manufacturing and clinical immunology. The company is primarily recognized for its development of skin test reagents designed to identify patients at risk for penicillin allergies. A cornerstone of its market presence is the PRE-PEN diagnostic skin test, an FDA-approved solution that has become a standard for healthcare providers seeking to mitigate risks associated with antibiotic administration. Through a strategic acquisition by ALK-Abelló, AllerQuest has transitioned its manufacturing and distribution capabilities, ensuring that its high-quality reagents remain accessible to the medical community. The organization leverages a multidisciplinary team of experts in science and medicine to maintain rigorous standards in allergy testing protocols.
How much funding has AllerQuest raised?
AllerQuest has raised a total of $399K across 2 funding rounds:
Debt
$150K
Debt
$249K
Debt (2020): $150K with participation from PPP
Debt (2021): $249K led by PPP
Key Investors in AllerQuest
PPP
Public-Private Partnership
What's next for AllerQuest?
Following the successful integration of its flagship product into the ALK-Abelló portfolio, AllerQuest is positioned to leverage its accumulated capital to refine its diagnostic pipeline. The current late-stage funding environment provides the necessary runway to explore further advancements in allergy testing methodologies. Strategic priorities likely include the expansion of diagnostic applications and the optimization of reagent stability, ensuring that healthcare providers continue to have access to reliable, evidence-based tools for patient safety. As the company evolves, its focus remains on bridging the gap between complex pharmaceutical research and practical clinical application, ultimately enhancing the standard of care for patients with suspected antibiotic sensitivities.
See full AllerQuest company page
